Sensitivity of APTIMA HPV @entity32454 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed XXXX .

@entity5 @entity14043 @entity32454 @entity3
UNASSIGNED: The sensitivity of @entity32454 mRNA-based Aptima HPV test (AHPV; Hologic Inc) for detection of cervical @entity5 has been reported based on only a small number of cases. We determined the sensitivity of AHPV in comparison with the DNA-based Hybrid Capture 2 HPV test ( @entity14043 ; Qiagen) for the detection of oncogenic HPV in a large number of @entity5 at the time of diagnosis using cervical samples obtained in ThinPrep (Hologic). Samples yielding discordant results were genotyped using Linear Array assay (LA; Roche). Of 396 cases tested, AHPV detected 377 (sensitivity, 95.2%; 95% CI: 93.1 - 97.3), and @entity14043 376 (sensitivity, 94.9%; 95% CI: 92.7 - 97.1) with an agreement of 97.2% (kappa 0.7; 95% CI: 0.54-0.87). Among six AHPV   +   / @entity14043 - cases, LA identified oncogenic HPV types in four including a type 73 and was negative in two. Among five AHPV-/ @entity14043 + cases, LA detected oncogenic HPV types in two including a type 73 and was negative in three. Of 14 AHPV-/ @entity14043 - cases, 13 were genotyped. LA detected oncogenic HPV types in six, non-oncogenic types in three, and was negative in four. This is the largest study to demonstrate the sensitivity of AHPV for the detection of @entity3 and this assay showed equal sensitivity to @entity14043 . This article is protected by copyright. All rights reserved.
